International Tuberous Sclerosis Conference Archives

TSC Preclinical Consortium – A Collaboration and Resource Opportunity

by admin | Jun 2, 2019

D. J. AGUIAR2, D. BRUNNER4, T. RUPP3, S. LEISER1, S. L. ROBERDS2 1PsychoGenics, Inc., Paramus, NJ, USA; 2Tuberous Sclerosis Alliance, Silver Spring, MD, USA; 3Porsolt, Le Genest-Saint-Isle, France; ;4Early Signal, New York. The TS Alliance Preclinical Consortium seeks...

PQR620 and PQR530 inhibit mTOR signaling in the brain leading to seizure prevention and extended survival in TSC animal models

by admin | Jun 2, 2019

P. HILLMANN,2 D. RAGEOT3, F. B. ILS2, P. HEBEISEN2, J.B. LANGLOIS3, C. BORSARI3, S. LEISER1, S. L. ROBERDS4, W. LOSCHER5, M. P. WYMANN3, D. FABBRO2 1PsychoGenics, Inc., Paramus, NJ, USA; 2PIQUR Therapeutics, Basel, Switzerland; 3Department of Biomedicine, Basel,...

TSC Preclinical Consortium – A Collaboration and Resource Opportunity

PQR620 and PQR530 inhibit mTOR signaling in the brain leading to seizure prevention and extended survival in TSC animal models

Recent Comments

CONTACT

Email: info@psychogenics.com

Phone: (914) 406-8019